Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease driven by autoimmune mechanisms, characterized by elevated serum aminotransferases, hypergammaglobulinemia, and interface hepatitis on histology. With an annual global incidence of 1.37 per 100,000, AIH can lead to severe outcomes such as cirrhosis or liver failure if untreated. Current first-line therapies, including glucocorticoids and azathioprine, aim for biochemical remission but are often limited by significant side effects and incomplete efficacy in some patients.